Metastatic Cancer Drug Market Growth and Size Projections 2030

The global metastatic cancer drug market is experiencing significant growth, driven by a rising prevalence of cancer and a growing aging population. The market is also benefitting from increased awareness of cancer and early screening initiatives. According to the World Health Organization (WHO), new cancer cases are expected to reach 29.4 million by 2040, highlighting the pressing need for effective cancer treatments.

Environmental Factors and Lifestyle Changes Contribute to Rising Cancer Cases

Several factors are contributing to the surge in cancer cases, including environmental variables such as cigarette use, changing dietary patterns, urbanization, and extended post-reproductive lifespans. Increased awareness of cancer and early screening efforts are also playing a role in the markets growth.

Geriatric Population Vulnerable to Metastatic Cancer

The aging population is particularly susceptible to metastatic cancer due to weakened immune systems. Studies show that in the United States, 60 percent of all cancer cases and 70 percent of cancer-related deaths occur in individuals aged 65 and above. This demographic trend is further propelling the demand for metastatic cancer drugs.

Targeted Therapy Dominates with Fewer Side Effects

Targeted therapy is expected to dominate the market in the coming years due to its advantages, including fewer adverse effects and tailored therapeutics that focus on specific molecular changes unique to each malignancy. Healthcare facilities improvements, increased healthcare spending in developed countries, and ongoing research in the life sciences are all driving the expansion of the targeted therapeutics segment.

North America Leads the Market

North America is at the forefront of the metastatic cancer drug market, with a large patient population, a robust healthcare infrastructure, favorable reimbursement policies, and a high level of research and development activities. The regions increased incidence of cancer, especially in the United States, has led to a surge in demand for cancer drugs.

Asia Pacific Shows Rapid Growth

The Asia Pacific region is experiencing rapid growth in the metastatic cancer drug market due to increasing cancer prevalence, government awareness campaigns, and patient aid programs. Factors such as population growth, aging, environmental pollution, and unhealthy lifestyles are contributing to the rising cancer burden in the region.

Competitive Landscape

Key players in the metastatic cancer drug market include Bayer AG, Johnson & Johnson, AstraZeneca PLC, F. Hoffmann-La Roche AG, Pfizer Inc., Bristol Myers Squibb Company, Amgen Inc., Merck & Co. Inc., AbbVie Inc., and Novartis AG.

Recent Developments

  • In July 2021, AstraZeneca received approval to market Imfinzi (durvalumab) in China for the treatment of unresectable Stage III non-small cell lung cancer.
  • Bayer AG announced an agreement in June 2021 to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc., expanding its cancer portfolio.

The metastatic cancer drug market is poised for continued growth as cancer cases continue to rise globally, emphasizing the importance of innovative treatments and therapies to combat this devastating disease.

Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Our Blogs:

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of

services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.


Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA (Toll-free) +1 (844) 3829746



LinkedIn | Twitter

This press release first seen on Brilad

comtex tracking


About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Feature Georgia Heralds was involved in the writing and production of this article.